BioCentury
ARTICLE | Finance

April 17 Quick Takes: Mabworks’ $160M series C; plus RDMD, PIC, SIRS, Atomo and Lantern

April 18, 2020 1:11 AM UTC

Beijing antibody play Mabworks raises $160M
Mabworks Biotech Co. Ltd. raised RMB1.1 billion ($160 million) in series C1 and C2 rounds to support development and commercialization of its antibody pipeline for various cancers, autoimmune, metabolic and infectious diseases. The round was co-led by CICC Qide Fund, Lyzz Capital, CITIC Securities Investment and Huge Capital with participation by SDIC, Lake Bleu Capital, Yuexiu Industrial Fund, E-Town International Investment, BOCOM International, Sealand Innovation Capital, Chinese Academy of Sciences Venture Capital, Silicon Paradise, Vigintillion Capital, Everest Venture Capital, Homsun Capital and Kang Chuang No. 1. The company’s most advanced candidate is in Phase III testing to treat non-small cell lung cancer (NSCLC).

Spark leads A round for real-world evidence company RDMD
Spark Capital led RDMD Inc.’s $14 million series A, which will enable the rare-disease focused real-world evidence company to expand into 20 additional indications. Existing seed investors Lux Capital, Village Global and Garuda Ventures, as well as new investor Maveron Capital, also participated in the round. RDMD engages patients with rare diseases to collect data that can guide drug developers to better design clinical trials or be used in lieu of a placebo...